Long-term Mortality in Patients with Ischaemic Heart Failure Revascularized with Coronary Artery Bypass Grafting or Percutaneous Coronary Intervention: Insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Overview
Authors
Affiliations
Aims: To compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for treatment of patients with heart failure due to ischaemic heart disease.
Methods And Results: We analysed all-cause mortality following CABG or PCI in patients with heart failure with reduced ejection fraction and multivessel disease (coronary artery stenosis >50% in ≥2 vessels or left main) who underwent coronary angiography between 2000 and 2018 in Sweden. We used a propensity score-adjusted logistic and Cox proportional-hazards regressions and instrumental variable model to adjust for known and unknown confounders. Multilevel modelling was used to adjust for the clustering of observations in a hierarchical database. In total, 2509 patients (82.9% men) were included; 35.8% had diabetes and 34.7% had a previous myocardial infarction. The mean age was 68.1 ± 9.4 years (47.8% were >70 years old), and 64.9% had three-vessel or left main disease. Primary designated therapy was PCI in 56.2% and CABG in 43.8%. Median follow-up time was 3.9 years (range 1 day to 10 years). There were 1010 deaths. Risk of death was lower after CABG than after PCI [odds ratio (OR) 0.62; 95% confidence interval (CI) 0.41-0.96; P = 0.031]. The risk of death increased linearly with quintiles of hospitals in which PCI was the preferred method for revascularization (OR 1.27, 95% CI 1.17-1.38, Ptrend < 0.001).
Conclusion: In patients with ischaemic heart failure, long-term survival was greater after CABG than after PCI.
Huang X, Sun T, Zhang B, Ma M, Chen Z, Zhao Z Ann Med. 2025; 57(1):2458200.
PMID: 39898975 PMC: 11792126. DOI: 10.1080/07853890.2025.2458200.
Research progress of two-pore potassium channel in myocardial ischemia-reperfusion injury.
Zhang Y, Li J, Pan J, Deng S Front Physiol. 2024; 15:1473501.
PMID: 39534859 PMC: 11554511. DOI: 10.3389/fphys.2024.1473501.
Lipoprotein(a) as a novel biomarker for predicting adverse outcomes in ischemic heart failure.
Zhang B, Xu Y, Huang X, Sun T, Ma M, Chen Z Front Cardiovasc Med. 2024; 11:1466146.
PMID: 39301496 PMC: 11410592. DOI: 10.3389/fcvm.2024.1466146.
Lee Chuy K, Velazquez E, Lansky A, Jamil Y, Ahmad Y J Soc Cardiovasc Angiogr Interv. 2024; 2(6Part B):101197.
PMID: 39131064 PMC: 11307589. DOI: 10.1016/j.jscai.2023.101197.
Myocardial viability on trial.
Bolognese L, Reccia M Eur Heart J Suppl. 2024; 26(Suppl 1):i15-i18.
PMID: 38867871 PMC: 11167980. DOI: 10.1093/eurheartjsupp/suae005.